Literature DB >> 22585216

Pharmacokinetics of caspofungin in two patients with burn injuries.

V Jullien, B Blanchet, M Benyamina, M Tod, C Vinsonneau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22585216      PMCID： PMC3421601          DOI： 10.1128/AAC.00039-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 3.  Pharmacokinetics/pharmacodynamics of echinocandins.

Authors:  U Theuretzbacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-14       Impact factor: 3.267

Review 4.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.

Authors:  T H Nguyen; T Hoppe-Tichy; H K Geiss; A C Rastall; S Swoboda; J Schmidt; M A Weigand
Journal:  J Antimicrob Chemother       Date:  2007-05-24       Impact factor: 5.790

6.  Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

Authors:  Julie A Stone; Xin Xu; Gregory A Winchell; Paul J Deutsch; Paul G Pearson; Elizabeth M Migoya; Goutam C Mistry; Liwen Xi; Alisha Miller; Punam Sandhu; Romi Singh; Florencia deLuna; Stacy C Dilzer; Kenneth C Lasseter
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  6 in total
  4 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

2.  Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.

Authors:  M J Asensio; M Sánchez; B Galván; E Herrero; L Cachafeiro; A Agrifoglio; E Perales; S Luque; A García-de-Lorenzo
Journal:  Intensive Care Med       Date:  2014-12-03       Impact factor: 17.440

3.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

4.  Population Pharmacokinetics of Caspofungin among Extracorporeal Membrane Oxygenation Patients during the Postoperative Period of Lung Transplantation.

Authors:  Qianlin Wang; Zhu Zhang; Donglin Liu; Wenqian Chen; Gang Cui; Pengmei Li; Xianglin Zhang; Min Li; Qingyuan Zhan; Chen Wang
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.